MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

Search

Catalyst Pharmaceuticals Inc

Closed

SectorHealthcare

21.47 1.71

Overview

Share price change

24h

Current

Min

21.1

Max

21.53

Key metrics

By Trading Economics

Income

801K

57M

Sales

-399K

141M

P/E

Sector Avg

13.771

39.857

Profit margin

40.119

Employees

181

EBITDA

526K

73M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+57.37% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-369M

2.7B

Previous open

19.76

Previous close

21.47

Technical Score

By Trading Central

Confidence

Bearish Evidence

Catalyst Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

17 Jul 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 Jul 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 Jul 2025, 21:04 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 Jul 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 Jul 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 Jul 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 Jul 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 Jul 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 Jul 2025, 22:43 UTC

Acquisitions, Mergers, Takeovers

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 Jul 2025, 22:43 UTC

Acquisitions, Mergers, Takeovers

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 Jul 2025, 22:40 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 Jul 2025, 22:40 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 Jul 2025, 22:30 UTC

Market Talk
Earnings

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 Jul 2025, 22:20 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

17 Jul 2025, 22:20 UTC

Market Talk
Earnings

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 Jul 2025, 22:04 UTC

Market Talk
Earnings

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 Jul 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 Jul 2025, 21:58 UTC

Market Talk
Earnings

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 Jul 2025, 21:57 UTC

Earnings

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 Jul 2025, 21:47 UTC

Earnings

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 Jul 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Jul 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 Jul 2025, 21:38 UTC

Acquisitions, Mergers, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 Jul 2025, 21:22 UTC

Acquisitions, Mergers, Takeovers

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 Jul 2025, 21:05 UTC

Earnings

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 Jul 2025, 21:04 UTC

Acquisitions, Mergers, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 Jul 2025, 21:02 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 Jul 2025, 20:59 UTC

Acquisitions, Mergers, Takeovers

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 Jul 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

17 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Catalyst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

57.37% upside

12 Months Forecast

Average 33.33 USD  57.37%

High 35 USD

Low 31 USD

Based on 4 Wall Street analysts offering 12 month price targets forCatalyst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 24.28Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.